[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Singapore General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":695},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,50,89,117,144,177,197,227,255,279,305,329,352,371,402,429,458,485,510,538,563,590,617,646,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053812","durian-consumption-in-adults-with-type-2-diabetes-mellitus-100053812",false,"NCT07697612","Durian Consumption in Adults With Type 2 Diabetes Mellitus","Durian Consumption on Human Microbiome and Metabolome in Adults With Type 2 Diabetes Mellitus (DURIOME-T2D)","DURIOME-T2D","Inclusion Criteria:\n\n1. Age 21 to 70 years.\n2. Diagnosis of type 2 diabetes mellitus.\n3. Agrees to consume durian for 2 weeks.\n4. Body mass index 25 to 40 kg\u002Fm².\n\nExclusion Criteria:\n\n1. Known or suspected intolerance or allergy to durian.\n2. Known skin reaction to adhesives used in a continuous glucose sensor.\n3. Uncontrolled diabetes (HbA1c greater than 8.5%).\n4. Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol\u002FL).\n5. Smoking.\n6. Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy.\n7. Inflammatory bowel disease.\n8. Glomerular filtration rate less than 30 mL\u002Fmin.\n9. ALT greater than 3 times upper limit of normal.\n10. AST greater than 3 times upper limit of normal.\n11. Liver cirrhosis.\n12. Significant alcohol consumption, defined as more than 20 g\u002Fday for women and more than 30 g\u002Fday for men.\n13. Pregnant, breastfeeding, or intending to conceive during the study.\n14. Current hemorrhoids or piles causing rectal bleeding during stool passage.\n15. Systemic steroid use.\n16. Insulin use.\n17. Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine.\n18. Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month.\n19. Uncontrolled thyroid disease.\n20. Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation","ALL","21 Years","70 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","This single-arm clinical trial investigates the effects of daily durian consumption on the gut microbiome, host metabolome, and glucose metrics in adults with type 2 diabetes mellitus (T2DM). Forty adults with T2DM will undergo a pre-durian phase, a durian consumption phase, and a post-durian phase, each lasting 10 to 14 days. Participants will attend five visits at Singapore General Hospital for clinical assessments, continuous glucose monitoring, fasting blood collection, stool sample collection, and dietary and stool record submission. The study aims to determine whether durian consumption alters microbiome and metabolomic profiles and whether it affects glycemic measures in adults with T2DM.",[29],"Type 2 Diabetes",[31,32,33,34,35,36],"Durian","Gut Microbiome","Metabolome","Continuous Glucose Monitoring","Precision Nutrition","Type 2 Diabetes Mellitus","NOT_YET_RECRUITING","2026-07-06",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":23},"2026-08",{"date":45,"type":23},"2027-12",{"name":47,"class":48},"Singapore General Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":49},"100633481","phase-2-improving-vaccine-protection-for-adults-100633481","NCT07527247","Improving Vaccine Protection for Adults","Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity","Inclusion Criteria:\n\n* Adults aged 21 to 59 years of age at time of screening.\n* BMI 18.5 - 27.5 kg \u002F m2 (BMI values for Asian population according to MOH guideline NIH Consensus Conference).\n* Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. For subjects with underlying comorbidities, the conditions must be deemed stable by the investigators, and they must not have any hospitalisation relating to these conditions in the last 6 months.\n* Voluntarily participate, understand and sign an informed consent form approved by the Ethical Review Board.\n* Subjects who are willing to comply with the requirements of the study protocol and scheduled visits. These requirements include completion of the subject diary, return for follow-up visits. Subjects should also be willing to make themselves available for the duration of the study, with access to a consistent means of contact.\n* Accessible vein at the forearm for blood taking.\n* Female subjects of non-childbearing potential due to surgical sterilisation (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Post-menopausal subjects must have had at least 12 months of natural (spontaneous) amenorrhoea.\n\nExclusion Criteria:\n\n* Previous vaccination against yellow fever, dengue either with a registered product or from participation in a previous vaccine study.\n* Previously received AS01-adjuvanted vaccines (e.g. Recombinant zoster vaccine, RTS,S\u002FAS01, RSVPre-F3-AS01), either with a registered product or from participation in a previous vaccine study.\n* Planned administration of a AS01-adjuvanted vaccine or yellow fever vaccine other than the study vaccine during the study.\n* Subjects who have been unwell in the last 7 days prior to screening.\n* History of documented yellow fever and \u002F or dengue infection.\n* Dengue seropositivity upon screening.\n* History of smoking within the last 1 year.\n* Planned travel to yellow fever endemic countries during the study.\n* Known allergy to AS01 and YF17D vaccine or their components (e.g. egg products).\n* Diagnosis of diabetes HBA1c \\> 6.5 according to American Diabetes Association criteria62.\n* Any medical condition that in the judgment of the investigator will make intramuscular injection unsafe (e.g. thrombocytopenia with platelet count \\\u003C 50x10\\^9\u002FL, coagulopathy, anti-coagulant therapy).\n* Risk factor for live-attenuated vaccines, including any confirmed or suspected primary or acquired immunodeficiency based on history and physical examination:\n\n  * History of thymus gland disease\n  * Haematologic neoplasms including leukaemia, lymphoma, myelodysplastic syndromes\n  * Diagnosed with cancer or treatment for cancer (except for localised basal cell carcinoma) within 3 years prior to screening\n  * Post-transplant: solid organ and haematopoietic stem cell transplant\n  * Immunocompromised due to primary or acquired (including HIV\u002FAIDS) immunodeficiency\n  * Other significantly immunocompromising conditions\n* Administration of anti-inflammatory drugs for the past 7 days (e.g. NSAIDs, Paracetamol, aspirin).\n* Use of metformin for the last 1 month.\n* Use of corticosteroids within the last 6 months prior to the first vaccine dose (defined as prednisolone \\> 10 mg \u002F day or equivalent for \\> 2 weeks, or prednisolone \\> 40mg \u002F day or \\> 1 week). Inhaled and topical steroids are allowed.\n* Received biologics (such as anti-TNF inhibitors, IL-1 inhibitors, co-stimulation blockers, B-cell depleting therapy) for the last 12 months.\n* Any condition (e.g. extensive psoriasis, chronic pain syndrome, severe hearing loss, cognitive impairment, dialysis, autoimmune disorders) that in the opinion of the investigator, would complicate or compromise the study or wellbeing of the subject, or prevent completion of the study.\n* Evidence of substance abuse, or previous substance abuse.\n* Clinically significant anaemia (Hb \\\u003C 10 g\u002FdL).\n* Blood donation exceeding \\> 450 ml in the past 3 months.\n* Participation in a study involving administration of an investigational or non-investigational compound within the past four months or planned participation during the duration of this study.\n* Administration of any licensed vaccine within 30 days before the first study vaccine dose or planned to receive such products within 30 days after the study vaccination.\n* Received immunoglobulin or any blood products within the 90 days preceding the first dose of study vaccine or planned to receive such products during the study period.",true,"59 Years",{"count":22,"type":23},[61],"PHASE2","As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.",[64,65],"Immune System Responses and Trained Immunity After AS01 Administration","Healthy Adult",[67,68,69,70,71,72,73,74,75,76,77,78,79],"AS01","AS01 adjuvant","Immune durability","Immune system","Immune response modulation","Recombinant zoster vaccine adjuvant","Vaccine","Randomized","Placebo-controlled","Blinded","Healthy volunteers","Protective effects","Yellow Fever Vaccine","RECRUITING","2026-06-11",{"date":83,"type":41},"2026-06-15",{"date":85,"type":41},"2025-11-06",{"date":87,"type":23},"2029-02-28",{"name":47,"class":48},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":49},"100642711","silver-impregnated-dressings-for-catheter-exit-site-and-tunnel-infections-in-peritoneal-dialysis-patients-100642711","NCT07641491","Silver-Impregnated Dressings for Catheter Exit-Site and Tunnel Infections in Peritoneal Dialysis Patients","Silver-Impregnated Dressings for the Management of Catheter Exit-Site Infection or Tunnel Infection in Peritoneal Dialysis Patients: A Pilot Study","Inclusion Criteria:\n\n* Adults aged 21 to 90 years\n* Currently receiving peritoneal dialysis under the Singapore General Hospital Peritoneal Dialysis Programme\n* Diagnosed with an active catheter exit-site infection or tunnel infection based on standard clinical criteria\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to silver dressings\n* Pregnant\n* Expected life expectancy of less than 6 months\n* Unable to provide informed consent\n* Currently participating in another clinical study involving exit-site care or wound dressings\n* Planned removal of the peritoneal dialysis catheter within the next 7 days","90 Years",{"count":98,"type":23},60,[26],"The goal of this clinical trial is to evaluate the feasibility and acceptability of using silver-impregnated dressings, compared to standard daily topical antibiotic exit-site dressings, for the management of catheter exit-site infection or tunnel infection in adult patients undergoing peritoneal dialysis. The study also aims to explore infection resolution, safety, and clinical outcomes associated with this alternative exit-site care approach.\n\nThe main questions it aims to answer are:\n\nIs the use of silver-impregnated dressings feasible and acceptable for peritoneal dialysis patients with exit-site or tunnel infection? Does the use of silver-impregnated dressings result in faster resolution of catheter exit-site or tunnel infection? Does replacing daily topical antibiotic dressings with silver-impregnated dressings reduce the frequency of dressing changes and the time spent on exit-site care? Are there any adverse events associated with the use of silver-impregnated dressings? What infection-related clinical outcomes occur, including recurrence of infection, need for catheter removal, or infection-related hospitalisation?\n\nStandard management of catheter exit-site or tunnel infection typically includes daily exit-site cleansing, application of topical antibiotics, sterile dressing coverage, and systemic antibiotic therapy. Despite these treatments, some patients continue to experience persistent or recurrent infections and adverse outcomes such as peritonitis, catheter loss, or transfer to haemodialysis.\n\nParticipants will:\n\nBe randomly assigned to receive either silver-impregnated dressings or standard exit-site care with daily topical antibiotic dressings as alternative approaches to local exit-site management Continue to receive systemic antibiotics according to current clinical guidelines Attend regular clinic visits for exit-site assessment and monitoring Be followed for up to twelve weeks to evaluate feasibility, safety, patient experience, and infection-related outcomes\n\nThe results of this pilot study will help evaluate whether silver-impregnated dressings are a feasible and acceptable alternative to standard topical antibiotic exit-site dressings for managing catheter-related infections in peritoneal dialysis patients and will inform the design of future larger clinical studies.",[102,103],"Peritoneal Dialysis Catheter Exit Site Infection","Peritoneal Dialysis Catheter Tunnel Infection",[105,106,107,108,109],"peritoneal dialysis","exit-site infection","tunnel infection","standard exit-site care","silver-impregnated dressings","2026-06-07",{"date":81,"type":41},{"date":113,"type":23},"2026-06",{"date":115,"type":23},"2027-03",{"name":47,"class":48},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":49},"100640639","phase-2-complementary-herbal-approach-to-rheumatoid-management-study-charms-100640639","NCT07627893","Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)","CHARMS","Inclusion Criteria:\n\n1. Patients between the ages of 21 and 70 years, and diagnosed with RA by a rheumatologist and fulfilling the 2010 ACR\u002FEULAR classification criteria for RA.\n2. Active disease with DAS28 ESR ≥3.2 at screening, with at least 6 swollen joints out of 66 and at least 6 tender joints out of 68.\n3. Receiving stable doses of methotrexate therapy for at least 3 months, and on stable dose for at least 4 weeks before trial entry ( ≥10mg per week), either subcutaneous or orally.\n4. Stable doses of non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, or oral corticosteroids (equivalent to prednisone ≤ 10 mg) for at least 4 weeks prior to first dose of study medication.\n5. Except for methotrexate, patients must have discontinued all csDMARDs, including, but not limited to: hydroxychloroquine, sulfasalazine, leflunomide prior to first dose of study medication as specified below:\n\n   1. ≥ 4 weeks prior to Baseline Visit for sulfasalazine and hydroxychloroquine\n   2. ≥ 8 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to an elimination procedure (i.e., 11 days with cholestyramine, or 30 days washout with activated charcoal)\n6. A negative urine pregnancy test for women of childbearing potential on Day 1 (prior to administration of first dose of study drug).\n7. Use of a reliable method of contraception by all female patients of childbearing potential and male patients with procreative capacity during the study and up to 3 months after the last dose of the study medication.\n\nExclusion Criteria:\n\n1. Not able to provide informed consent.\n2. Previous lack of efficacy to Si Miao Xiao Bi Tang.\n3. History of inflammatory joint disease other than RA. Secondary Sjogren's Syndrome is permitted.\n4. Concurrent use of other immunosuppressant medications, except MTX and protocol allowed doses of steroids.\n5. Has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point administration of corticosteroids in the preceding 4 weeks prior to the Baseline Visit.\n6. Subject has been treated with any investigational drug within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline Visit or is currently enrolling in another clinical study.\n7. Pregnant or breastfeeding females.\n8. Infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses, untreated malignancy, or evidence of active or untreated latent tuberculosis.\n9. Receipt of any live vaccine within 1 month prior to the Screening Visit, or expected need of live vaccination during study participation including up to 1 month after the last dose of study drug.\n10. History of clinically significant hematologic, pulmonary, renal, hepatic, or psychiatric disease that would interfere with the subject's participation in this study.\n11. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Day 1 or oral anti-infectives within 14 days prior to the Baseline Visit.\n12. Any uncontrolled clinically significant laboratory abnormality or any of the following laboratory abnormalities:\n\n    1. Evidence of hematopoietic disorder or hemoglobin \\\u003C9 g\u002FdL\n    2. White blood cell count \\\u003C3.0 x 10\\^9\u002FL (\\\u003C3000\u002Fmm\\^3)\n    3. Absolute neutrophil count \\\u003C1.2 x 10\\^9\u002FL (\\\u003C1000\u002Fmm\\^3)\n    4. Platelet count \\\u003C100 x 10\\^9\u002FL (\\\u003C100,000\u002Fmm\\^3)\n    5. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal (ULN)\n    6. Estimated glomerular filtration rate of less than 60 mL\u002Fmin\n13. Any arrhythmia on baseline\u002Fscreening ECG.\n14. Females of childbearing potential not willing to use contraceptive methods which, in the opinion of the investigator, are effective and adequate while on the study. Female subjects who are not of childbearing potential must meet at least one of the following criteria: (a) Have undergone a documented hysterectomy and\u002For bilateral oophorectomy; or (b) Achieved postmenopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause.\n15. Been diagnosed with G6PD deficiency.\n16. Subjects who are taking TCM supplements regularly (daily) and not willing to stop intake.",{"count":125,"type":23},132,[61,127],"PHASE3","Rheumatoid Arthritis (RA) is a chronic disease characterised by symmetric, polyarticular pain and swelling, involving small joints of the hands and feet. RA can lead to irreversible joint damage without treatment, causing disability and impacting daily activities and work productivity. Some patients turn to Chinese Herbal Medication (CHM) for treatment. Since there is currently no well designed randomised controlled trial to support the 'real-world' use of Si Miao Xiao Bi Tang with anti-rheumatic drugs, such as methotrexate, the investigators are conducting a 12-week, randomised double-blinded placebo-controlled trial to determine the efficacy, safety and cost effectiveness of a modified Si Miao Xiao Bi Tang, a type of CHM, in the treatment of patients with active RA.",[130],"Rheumatoid Arthritis (RA)",[132,133,134,135],"Rheumatoid Arthritis","Chinese Herbal Medicine","Traditional Chinese Medicine","Si Miao Xiao Bi","2026-06-02",{"date":138,"type":41},"2026-06-04",{"date":140,"type":23},"2026-06-01",{"date":142,"type":23},"2030-06-30",{"name":47,"class":48},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":49},"100638469","ap-noses-a-prospective-multicentre-registry-of-natural-orifice-specimen-extraction-in-minimally-invasive-colorectal-surgery-100638469","NCT07615036","AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery","AP-NOSES: A Prospective, Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery Across the Asia-Pacific Region","AP-NOSES","Inclusion Criteria:\n\n* Age 21 years or older\n* Elective minimally invasive colorectal resection (laparoscopic or robotic intent)\n* Planned intact specimen extraction\n* Eligible for natural orifice specimen extraction (NOSE) or transabdominal specimen extraction according to study protocol\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Emergency colorectal surgery\n* Planned transanal total mesorectal excision (TaTME)\n* Planned ultralow anterior resection with planned anastomosis 3 cm or less from the anal verge\n* Planned abdominoperineal resection (APR)\n* Planned permanent end stoma without restoration of intestinal continuity\n* Planned multivisceral resection\n* Generalized peritonitis or uncontrolled intra-abdominal sepsis\n* Pregnancy\n* Pre-existing ventral or incisional hernia at the planned extraction site\n* Planned specimen extraction through a prior laparotomy incision containing mesh\n* Fixed distal obstruction, severe pelvic stenosis, or other anatomical constraint precluding intact specimen extraction",{"count":153,"type":23},800,"OBSERVATIONAL","Natural orifice specimen extraction (NOSE) is a minimally invasive colorectal surgical technique in which the surgical specimen is removed through a natural orifice, including transanal or transvaginal routes, thereby avoiding an abdominal extraction incision. Observational studies suggest that NOSE may reduce wound-related morbidity and improve postoperative recovery, but prospective multicenter data evaluating long-term outcomes remain limited.\n\nAP-NOSES is a prospective, multicenter observational registry evaluating clinical, patient-reported, and long-term wound outcomes following minimally invasive colorectal surgery with NOSE or transabdominal specimen extraction. The primary objective is to compare time to incisional hernia within 24 months between NOSE-eligible patients undergoing planned NOSE extraction and NOSE-eligible patients undergoing planned transabdominal extraction.\n\nSecondary objectives include evaluation of postoperative complications, extraction-related morbidity, bowel function, urinary and sexual function, oncologic outcomes, and long-term patient-reported and clinical outcomes across participating centers.\n\nThis study does not alter routine clinical care. Surgical technique, perioperative management, and follow-up are performed according to local institutional practice.",[157,158],"Colorectal Neoplasms","Incisional Hernia",[160,161,162,163,164,165,166,167,168],"Natural Orifice Specimen Extraction","NOSE surgery","Minimally invasive colorectal surgery","Incisional hernia","Laparoscopic colorectal surgery","Transanal specimen extraction","Transvaginal specimen extraction","Patient-reported outcomes","Prospective registry","2026-05-22",{"date":171,"type":41},"2026-05-29",{"date":173,"type":41},"2026-05-05",{"date":175,"type":23},"2033-12-30",{"name":47,"class":48},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":49},"100484500","doctor-patient-partnerships-the-key-to-a-better-standard-of-medical-advice-100484500","NCT05588856","Doctor-patient Partnerships: the Key to a Better Standard of Medical Advice?","Inclusion Criteria:\n\n* Recruitment of all participants will be through the Singapore General Hospital ambulatory clinic or general ward.\n\nAll patients must have a confirmed diagnosis of the chronic lung disease that is consistent with international guidelines. The diagnosis will be verified by the managing physician Informed consent forms will be signed. We will aim for purposive and maximum variation sampling.\n\nExclusion Criteria:\n\n* None of the above","99 Years",{"count":185,"type":23},300,"Background: The current legal standard of advice in Singapore has three components: distinction of advice from the other parts of clinical consultation (i.e. diagnosis and treatment) for the purpose of standard setting, categories of information that need to be disclosed to patients and how the adequacy of this information is judged in court. A review of empirical data shows that information deficit is not the only or most pressing concern in decision-making from the patients' perspective. The data also reflects the value that is placed on relationships that patients have with their treating doctors. Features of a good doctor-patient relationship can be found in partnerships, which are based on therapeutic alliance and mutuality.\n\nObjective: To develop a contextual understanding of the role of clinical partnerships in Singapore, empirical data is needed from both patients and healthcare workers on their understanding and interpretation of doctor-patient partnerships and how medical decisions are made using this relationship.\n\nDesign: A qualitative study using interpretive analysis of semi-structured interviews conducted via in-person, telephone and videoconferencing interviews.",[188],"Doctor-Patient Relation","2026-05-13",{"date":191,"type":41},"2026-05-18",{"date":193,"type":41},"2021-06-17",{"date":195,"type":23},"2027-05-01",{"name":47,"class":48},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100589057","effectiveness-of-large-language-model-for-anaesthesia-and-procedural-consent-100589057","NCT06949462","Effectiveness of Large Language Model for Anaesthesia and Procedural Consent","Evaluating the Effectiveness of Large Language Models in Anaesthesia and Procedural Consent: A Comparative Analysis With Traditional Patient Consent Methods","PEAR","Inclusion Criteria:\n\n\\- Adults (≥21 years old) undergoing elective surgery requiring anaesthesia\n\nClassified as ASA Physical Status I to III\n\n* Able to provide informed consent\n* Able to communicate effectively in English, Chinese (Mandarin), Malay, or Tamil\n* Willing and able to complete questionnaires and interact with the PEAR chatbot (intervention arm)\n\nExclusion Criteria:\n\n* ASA Physical Status IV or above\n* Cognitive impairment or psychiatric conditions that may limit comprehension or communication\n* Non-literate patients or those unable to understand English, Chinese, Malay, or Tamil\n* Emergency surgery cases\n* Prior participation in the study (to prevent bias)",{"count":206,"type":23},120,[26],"Patient understanding of anaesthesia risks remains inconsistent due to time constraints, language barriers, and variable clinician communication styles. Traditional verbal consent may not consistently ensure comprehension or reduce preoperative anxiety. PEAR (Patient Education of Anesthesia Risks) is a multilingual, AI-driven chatbot developed to enhance patient education and improve the quality of anaesthesia risk counselling.\n\nStudy Objective:\n\nTo compare PEAR's performance in delivering anaesthesia risk consent against the standard face-to-face verbal method.",[210,211,212],"Consent Forms","Anesthesia","Artificial Intelligence (AI)",[214,215,216,217],"Anaesthesia","Informed Consent","Large Language Model","Artificial Intelligence","2026-04-30",{"date":220,"type":41},"2026-05-07",{"date":222,"type":41},"2026-01-07",{"date":224,"type":23},"2026-04-27",{"name":47,"class":48},2,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":49},"100625380","pre-hospital-cooling-to-improve-cardiac-arrest-neurological-outcomes-precedence-100625380","NCT07421882","PRE-hospital Cooling to improvE carDiac arrEst Neurological outComEs (PRECEDENCE)","PRE-hospital Cooling to improvE carDiac arrEst Neurological outComEs (PRECEDENCE): a Pilot Feasibility Study","PRECEDENCE","Inclusion Criteria:\n\n1. Out-of-hospital cardiac arrest (OHCA) of any rhythm attended by Singapore Civil Defence Force (SCDF) paramedics.\n2. Return of spontaneous circulation (ROSC) achieved in the pre-hospital setting.\n3. Age ≥16 years and ≤80 years.\n4. Patient remains comatose after ROSC, with Glasgow Coma Scale (GCS) ≤8.\n\nExclusion Criteria:\n\n1. Age \\>80 years.\n2. Traumatic cause of cardiac arrest.\n3. Tympanic temperature \\\u003C34°C at time of assessment.\n4. Pregnant females.\n5. Termination of resuscitation in the Emergency Department.\n6. Withdrawal of life support within 24 hours of Coronary Care Unit (CCU) admission.","16 Years","80 Years",{"count":238,"type":23},50,[26],"The PRE-hospital Cooling to improvE carDiac arrEst Neurological outComEs (PRECEDENCE) study is a pilot feasibility trial evaluating the implementation of pre-hospital targeted temperature management (TTM) using a wearable surface cooling device (CarbonCool® vest) in adult out-of-hospital cardiac arrest (OHCA) patients with return of spontaneous circulation (ROSC). The study aims to assess feasibility, fidelity, acceptability, and safety of initiating cooling in the field by emergency medical services (EMS) prior to hospital arrival. Results will inform the design of a larger definitive trial to determine the clinical effectiveness of early pre-hospital TTM in improving neurological outcomes.",[242,243,244,245],"Out-Of-Hospital Cardiac Arrest","Cardiopulmonary Resuscitation","Death, Sudden, Cardiac","Therapeutic Hypothermia",[247],"Return of Spontaneous Circulation","2026-04-23",{"date":250,"type":41},"2026-04-29",{"date":252,"type":41},"2026-02-01",{"date":115,"type":23},{"name":47,"class":48},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":264,"briefSummary":265,"conditions":266,"keywords":272,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100612366","music-therapy-to-reduce-anxiety-and-pain-in-chronic-pain-patients-during-procedures-100612366","NCT07252648","Music Therapy to Reduce Anxiety and Pain in Chronic Pain Patients During Procedures","Effect of Peri-Operative Music Therapy on Anxiety, Pain Catastrophising, and Pain in Chronic Pain Patients Undergoing Interventional Pain Procedures - A Randomised Controlled Trial","Inclusion Criteria:\n\n* aged ≥21years\n* chronic pain ≥3 months\n* scheduled for interventional pain procedures\n\nExclusion Criteria:\n\n* presence of hearing impairment\n* lack of capacity to consent\n* non-interventional pain procedures, e.g. lignocaine infusion, ketamine infusion\n* pregnant women",{"count":263,"type":23},110,[26],"This study aims to find out whether listening to music before, during, and after pain procedures can help reduce anxiety, pain catastrophising, and acute pain in patients with chronic pain. Music therapy may provide a simple, safe, and non-drug way to help patients relax and feel more comfortable.\n\nIn this study, adult patients with chronic pain who are scheduled for interventional pain procedures at Singapore General Hospital will be randomly assigned to one of two groups. One group will listen to self-selected music through headphones and speakers before, during, and after the procedure. The other group will receive standard care without music.\n\nResearchers will measure anxiety, pain catastrophising, and pain levels before and after the procedure using validated questionnaires. The main outcome will be the level of anxiety after the procedure. Other outcomes include pain catastrophising scores, pain scores during local anaesthetic injection, and overall patient satisfaction.\n\nThis study will help determine if music therapy can be routinely used to improve comfort and emotional well-being for patients undergoing interventional pain procedures.",[267,268,269,270,271],"Chronic Pain","Anxiety","Music Therapy","Pain Perception","Pain Catastrophizing",[271,269,268,267],{"date":250,"type":41},{"date":275,"type":23},"2026-03-30",{"date":277,"type":23},"2026-12-31",{"name":47,"class":48},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100596177","trial-of-mobile-external-defibrillator-for-out-of-hospital-cardiac-arrest-in-singapore-100596177","NCT07042061","Trial of Mobile External Defibrillator for Out-of-hospital Cardiac Arrest in Singapore.","Out-of-Hospital Cardiac Arrest Care Through Empowered and Equipped Community First Responders: Mobile External Defibrillation Investigation for Cardiac Arrest in Singapore (MEDICS).","1.1. Inclusion Criteria\n\nStudy participants must meet all the inclusion criteria to participate in this study:\n\n1. Must be proficient in English. Able to read and understand English fluently.\n2. Be aged 21-74 years of age at point of recruitment.\n3. Willing and able to move rapidly to a scene that can be 400 meters away from their location.\n4. Be a registered CFR with SCDF.\n5. Must be active myResponder® mobile phone app user so they can receive alerts about nearby OHCA cases.\n\n1.2. Exclusion Criteria All subjects meeting any of the following exclusion criteria will be excluded from participation in this study.\n\n1. Not proficient in English. Cannot read and understand English.\n2. Aged less than 21 and over 74 years of age.\n3. Not willing to be a myResponder app user.\n4. Not able to move rapidly to a scene that can be 400 meters away from their location.\n5. Given the short duration of the trial, those who are pregnant will be ineligible.\n6. Those experiencing any serious physical injury or handicap and those with obvious mental handicap.","74 Years",{"count":288,"type":23},1000,[26],"The goal of this clinical trial is to learn the feasibility of equipping the volunteer community responders (VCR) with the mobile external automated defibrillators (mAEDs) for the management of adults experiencing out-of-hospital cardiac arrest (OHCA) patients. It will also provide early signals if this enhanced system can help increase the frequency of defibrillation and doing it earlier. The main questions it aims to answer are:\n\n* Can equipped VCRs apply mAEDs more frequently and earlier to potentially get more patients successfully resuscitated?\n* Is this system enhancement is feasible in the long run.\n\nParticipants, the VCRs, will:\n\n* Carry a 450 gm mAED with them all the time for up to an year and use it on an OHCA patient if and when alerted to help.\n* They will hand over this single-use battery-operated device to the EMS crew for data retrieval and potential replacement\n* They will be interviewed for their experience of being equipped and use of the mAED.",[292],"Out-of-hospital Cardiac Arrest (OHCA)",[294,295,296,297,298],"Out-of-hospital","Cardiac arrest","Automated external defibrillator","AED","Community volunteers",{"date":224,"type":41},{"date":301,"type":23},"2026-05-01",{"date":303,"type":23},"2027-01-31",{"name":47,"class":48},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":313,"briefSummary":314,"conditions":315,"keywords":319,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":226},"100598688","evaluate-the-feasibility-and-effectiveness-of-a-community-based-care-bundle-in-managing-and-preventing-pressure-injuries-100598688","NCT07074743","Evaluate the Feasibility and Effectiveness of a Community-based Care Bundle in Managing and Preventing Pressure Injuries","Inclusion Criteria\n\n* adult patients discharged from SGH with existing PI (any stages according to NPIAP and on any part of the body)\n* have a family caregiver or FDH who will be managing the PI upon discharge\n* patients will be discharged to home\n* living within the SGH nursing community zones\n\nExclusion Criteria\n\n* previous or existing participation in this trial\n* palliative or dying patients\n* planned discharge to a nursing home or other hospital\n* mobile inpatient care@home service\n* patient or next-of-kin who refused to participate.",{"count":312,"type":23},216,[26],"Community-acquired pressure injuries are pressure injuries that developed outside of hospital, typically in the patient's own home environment. Pressure injuries (PI) used to be commonly known as bedsores or pressure ulcers.\n\nThe goal of this clinical trial is to evaluate if a community-based pressure injury (PI) care bundle is effective in treating and preventing pressure injuries in home settings. It will also assess how feasible it is to implement this care bundle in Singapore's community care context.\n\nThe main questions it aims to answer are:\n\n1. Does the PI care bundle help improve pressure injury healing (shown by at least a 3-point reduction on the PUSH score)?\n2. Can the care bundle prevent the development of new pressure injuries?\n3. How well do caregivers learn and apply PI care knowledge after receiving the educational intervention?\n4. How practical and acceptable is this care bundle for use in home settings?\n\nThe investigators will compare the PI care bundle to routine care (control group) to see if the care bundle works better for managing pressure injuries at home. Success will be measured using the PUSH tool, which scores pressure injuries from 0 (completely healed) to 17 (most severe). A reduction of at least 3 points on this scale will indicate meaningful improvement.\n\nParticipants and their caregivers will:\n\nBe split into two groups - one group will use the new care plan (receive the PI care bundle), and the other will continue with their routine care.\n\nHave their pressure injuries checked regularly for 6 weeks. Have their caregivers learn about pressure injury care. Answer questions about how well the care plan works for them.\n\nThe investigator hopes this study will help find better ways to treat or prevent pressure injuries at home and support the caregivers at home.",[316,317,318],"Pressure Injuries","Caregiver","Community Dwelling Older Adult",[320,321,322],"pressure injuries","community nursing","care bundle",{"date":250,"type":41},{"date":325,"type":41},"2025-12-26",{"date":327,"type":23},"2028-06-30",{"name":47,"class":48},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":49},"100547544","multi-modal-training-program-to-promote-physical-activity-after-stroke-100547544","NCT06409351","Multi-modal Training Program to Promote Physical Activity After Stroke","Multi-mOdal Training Program to Promote Physical actIVity After sTrokE: MOTIVATE","Inclusion Criteria:\n\n* Aged 21 years and over\n* Haemorrhagic or ischaemic stroke\n* At least 6 months post-stroke\n* Living at home\n* Able to walk independently +\u002F- gait aid short distances (self-reported)\n* Have sufficient cognition and\u002For carer support to engage in the interventions (clinical judgement)\n* Agreement to undertake a supported self-management physical activity intervention programme\n\nExclusion Criteria:\n\n* Living in residential care\n* Unstable cardiac conditions, severe arthritis, or other conditions limiting the ability to exercise\n* Advised by GP\u002Fconsultant not to undertake moderate-intensity exercise for health reason\n* Currently already participating in physical activity that meets recommended levels (150mins of moderate-vigorous physical activity)\n* Enrolled in another physical activity intervention trial",{"count":206,"type":23},[26],"The goal of this study is to learn if a behavioral change intervention can improve physical activity in stroke survivors living in the community.\n\nThe main question it aims to answer is, if a behaviour change intervention and personalised physical activity prescription, are effective in improving the time spent in moderate to vigorous physical activity amongst chronic stroke survivors.\n\nResearchers will compare the intervention group to a control group, to see if physical activity counselling and a personalized physical activity prescription is more effective in improving moderate to vigorous physical activity, than usual care alone. The study period for each participant is 6 months. Assessments are conducted at month 1 (baseline), 3 and 6.\n\nThe control group will receive only usual care, which consists of an information sheet on physical activity with the following content: (1) Why be active and (2) How to be active (with URL links to resources and videos). The usual care is delivered at 3-time points during month 1, 3 and 6.\n\nThe intervention group will receive usual care and a behavioral change intervention. The behavioral change intervention consists of up to 6 individual physical activity counselling sessions and a personalized physical activity prescription. The 6 sessions will take place only during months 1 to 3 and there will be no intervention during months 4 to 6. Of the 6 sessions, 3 are conducted face-to-face and another 3 sessions will take place using telehealth methods such as phone, text messaging and videoconference. Participants can meet the study physiotherapist at their preferred exercise space during the 3 face-to-face sessions. The physical activity counselling sessions consist of goal setting and action planning, and problem-solving barriers around participation in physical activity. The overall aim is to increase time spent in moderate-vigorous physical activity.",[340,341],"Stroke","Physical Inactivity",[343,344,345,340],"Physical activity","Behavioural change","Implementation Science",{"date":224,"type":41},{"date":348,"type":41},"2024-06-11",{"date":350,"type":23},"2027-03-31",{"name":47,"class":48},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":49},"100634591","investigating-the-prevalence-and-risk-factors-for-sarcopenia-amongst-adults-seeking-treatment-for-obesity-100634591","NCT07541677","Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity","Inclusion Criteria:\n\n* body mass index ≥ 27.5kg\u002Fm2\n* able to provide informed consent.\n\nExclusion Criteria:\n\n* unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)\n* pregnant women\n* history of bariatric procedures or surgeries\n* on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)","100 Years",{"count":185,"type":23},"Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.\n\nIn this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.\n\nThe investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.\n\nCurrently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.",[362],"Obesity","2026-04-16",{"date":365,"type":41},"2026-04-21",{"date":367,"type":41},"2025-05-26",{"date":369,"type":23},"2027-04",{"name":47,"class":48},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":379,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":49},"100633938","patient-outcomes-following-kinematic-and-functional-alignment-in-robotic-assisted-total-knee-arthroplasty-with-randomized-insert-types-100633938","NCT07533188","Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomized Insert Types","A Prospective Randomized Controlled Trial Comparing Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty Using the VELYS System","VELYS RCT","\\*Inclusion Criteria:\\*\n\n* Patients undergoing robotic-assisted total knee arthroplasty using the VELYS system\n* Diagnosis of knee osteoarthritis requiring surgical intervention\n* Able to provide informed consent\n* Willing to complete patient-reported outcome measures\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Patients undergoing revision knee arthroplasty\n* Presence of active infection\n* Inability to comply with follow-up assessments\n* Severe co-morbidities that may affect surgical outcomes or participation in the study","18 Years",{"count":381,"type":23},240,[26],"This study aims to evaluate patient outcomes following robotic-assisted total knee arthroplasty using the VELYS system. Patients undergoing surgery will receive either kinematic alignment or functional alignment as determined by the operating surgeon as part of routine clinical care. Within each surgical technique group, patients will be randomly assigned to receive different implant insert types (medial stabilised or cruciate retaining) using a REDCap-based randomisation process. Patient-reported outcome measures will be collected before surgery and at follow-up time points after surgery to assess clinical outcomes.",[385,386],"Knee Osteoarthritis","Degenerative Joint Disease of the Knee",[388,389,390,391,392,393,394,395],"Robotic-Assisted Total Knee Arthroplasty","VELYS System","Kinematic Alignment","functional Alignment","Medial Stabilized Insert","Cruciate Retaining Insert","Patient-Reported Outcomes","Total Knee Replacement",{"date":365,"type":41},{"date":398,"type":41},"2025-10-14",{"date":400,"type":23},"2027-10-14",{"name":47,"class":48},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":24,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":49},"100556847","enhanced-community-first-responder-system-evaluation-in-singapore-100556847","NCT06530433","Enhanced Community First Responder System Evaluation in Singapore","Evaluation of an Enhanced Community First Responder Support System to Improve Bystander Cardiopulmonary Resuscitation Quality for Patients Experiencing Out-of-hospital Cardiac Arrest","TCPR-Link","Inclusion Criteria:\n\n* 18 years old and above\n* SCDF registered CFRs\n* Trial dispatchers with an active account of myResponder® app on their mobile phones\n\nExclusion Criteria:\n\n* The CFRs who are pregnant\n* Experiencing any serious physical Conditions\n* Mental Health Conditions",{"count":411,"type":23},165,[26],"The rise in out-of-hospital cardiac arrest (OHCA) cases in Singapore highlights the need for effective bystander cardiopulmonary resuscitation (BCPR). Despite many lay responders performing CPR, survival rates with good neurological outcomes have not significantly improved, prompting research into the quality of CPR as a critical factor. The study by Gallagher EJ et al. showed a significant survival improvement with high-quality CPR.\n\nTo address this, the Unit of Pre-hospital and Emergency Research (UPEC) trained thousands of community first responders (CFRs) in simplified CPR techniques using hands-only and DA-CPR methods. A significant innovation is the CPRcard®, developed by Laerdal in Norway, which offers real-time feedback on the quality of chest compressions. However, only 36% of CFRs using the CPRcard® achieved the desired compression standards, indicating room for improvement.\n\nThe study proposes enhancing CFR support with information communication technology (ICT), enabling two-way audio and one-way video communication between CFRs and dispatchers. This aims to reduce stress among responders, increase their willingness to engage with OHCA alerts, and improve CPR quality.\n\nThe clinical trial in Singapore will compare the current system against the enhanced CFR support system (eCSS), focusing on the real-time relay of CPR performance data, communication ease, and implementation factors. The high-quality CFR and OHCA registries in Singapore provide a robust setting for this research, aiming to enhance CPR delivery and improve OHCA outcomes through technology and real-time support.",[242],[416,417,418,419,420],"cardiopulmonary resuscitation","Bystander CPR","Community first responder","CPRCard","TCPR Link","2026-04-08",{"date":423,"type":41},"2026-04-13",{"date":425,"type":41},"2024-08-01",{"date":427,"type":23},"2028-12-31",{"name":47,"class":48},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":439,"briefSummary":441,"conditions":442,"keywords":447,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":49},"100611947","phase-1-integrating-allogeneic-nk-cells-in-high-risk-advanced-stage-iii-iv-nasopharyngeal-cancer-patients-100611947","NCT07247201","Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","Phase 1\u002F2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","AlloNK1","Inclusion Criteria:\n\n* Diagnosed with NPC Stage III-IVA\u002FB (T1-4, N1-3, M0)\n* Able to tolerate convectional CRT\n* Detectable EBV level at diagnosis\n* Adequate organ function ANC ≥ 1500\u002FµL Platelet count ≥ 100,000\u002FµL Creatinine clearance ≥60ml\u002Fminute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 2 x upper limit normal ALT ≤ 2 x upper limit normal\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* History of Autoimmune Disease or any condition resulting in immunocompromised state (e.g., Drug induced)\n* ECOG performance status above or equal to 2\n* Poor Organ Function\n* Lactating or pregnant\n* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study.",{"count":438,"type":23},31,[440,61],"PHASE1","This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and to identify the highest safe and tolerable dose of allogeneic NK cells. Allogeneic NK cells, derived from healthy donors, have demonstrated good tolerability in cancer patients.\n\nThe primary research questions are:\n\n1. What is the maximum tolerated dose (MTD) of allogeneic NK cells when administered with CRT in NPC patients?\n2. Can the addition of allogeneic NK cells to standard CRT reduce the proportion of NPC patients with detectable plasma EBV-DNA from 30% to 10%?\n\nPhase 1: Participants will receive one of five escalating doses of allogeneic NK cells with CRT to determine the MTD.\n\nPhase 2: Participants will receive the established MTD NK dose together with CRT.\n\nParticipants will undergo regular safety monitoring, side-effect assessment, measurement of plasma EBV-DNA levels, and surveillance for disease recurrence.",[443,444,445,446],"Nasopharyngeal Carcinoma (NPC)","Minimal Residual Disease","Recurrent Nasopharyngeal Carcinoma","Maximum Tolerated Dose",[448,449,450,446],"Advanced Nasopharyngeal Cancer","Epstein-Barr Virus DNA","Allogeneic NK Cells","2026-03-24",{"date":275,"type":41},{"date":454,"type":23},"2026-04",{"date":456,"type":23},"2026-09",{"name":47,"class":48},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":24,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":49},"100627707","ai-powered-closed-loop-multielectrode-transcutaneous-spinal-cord-stimulation-real-time-adjustments-for-enhanced-motor-recovery-in-spinal-cord-injury-aim-recover-100627707","NCT07452133","AI-Powered Closed-Loop Multielectrode Transcutaneous Spinal Cord Stimulation: Real-Time Adjustments for Enhanced Motor Recovery in Spinal Cord Injury (AIM RECOVER)","AIM RECOVER","Inclusion Criteria:\n\nHealthy volunteers:\n\n1. Adults aged 21 years or older with the mental capacity to provide informed consent.\n2. No prior diagnosis of neuromuscular or neurological conditions affecting the lower limbs.\n3. Able to walk independently with a normal gait pattern, as confirmed by clinical observation done by the study team.\n\nSCI patients:\n\n1. Age 21 -75 years;\n2. Non-progressive, incomplete SCI (traumatic or non-traumatic).\n3. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) \u002FASIA Impairment scale (AIS) grade B, C, or D, with Lower Extremity Motor Scores (ISNCSCI-LEMS) less than or equal to 40;\n4. Injury level at\u002Fabove L1 (above conus medullaris) with intact segmental reflexes below level of lesion;\n5. Able to provide informed consent;\n6. No contraindication for tSCS, such as pace makers or other implantable electrical devices;\n7. Eligible for body-weight support treadmill training;\n8. Able to stand with body weight support and\u002For assistance.\n\nExclusion Criteria:\n\nHealthy voluteers:\n\n1. Presence of significant or unstable medical comorbidities, including uncontrolled cardiopulmonary disease or severe cognitive impairment, as determined by the study team.\n2. Diagnosis of any neuromuscular or musculoskeletal disorders (e.g., congenital skeletal deformity, limb amputation, neurological disorders, myopathy).\n3. Abnormal gait pattern due to underlying medical co-morbidities, as identified through physical examination and clinical assessment, and confirmed by the study team.\n4. Current pregnancy.\n\nSCI patients:\n\n1. Significant or unstable medical co-morbidities, including uncontrolled cardiopulmonary disease, severe cognitive impairment, or severe dysautonomia, as determined by the study team;\n2. Uncontrolled neuropathic or musculoskeletal pain, or contractures affecting participation in therapy;\n3. Known history of peripheral nerve injury (e.g., traumatic nerve injury, entrapment neuropathy);\n4. Pregnancy;\n5. Active malignancy or ongoing cancer treatment;\n6. Skin conditions (e.g., ulcers, infections, malignant lesions) that limit the application of tSCS electrodes;\n7. Prior exposure to tSCS or eSCS interventions.","75 Years",{"count":467,"type":23},7,[26],"Spinal cord injury (SCI) often results in persistent motor deficits that are inadequately addressed by conventional rehabilitation. Transcutaneous spinal cord stimulation (tSCS) is a promising non-invasive neuromodulatory approach that can enhance motor activation and gait performance; however, current tSCS systems rely on static, pre-programmed stimulation parameters that do not adapt to real-time motor output or task demands. This limitation may reduce muscle selectivity and disrupt the spatiotemporal dynamics of spinal network activation required for functional movement.\n\nThis study aims to develop and evaluate an AI-powered closed-loop multielectrode tSCS system that dynamically adjusts stimulation parameters in real time based on kinematic and surface electromyography (EMG) feedback during walking in individuals with incomplete SCI. The study will compare immediate muscle recruitment and motor performance between conventional static tSCS and dynamic, targeted tSCS guided by real-time physiological signals.\n\nThe investigators hypothesize that AI-driven closed-loop tSCS will be safe and feasible, and will result in superior muscle activation patterns and improved gait performance compared with static stimulation. Findings from this study will provide foundational evidence for adaptive neuromodulation strategies and support the advancement of next-generation, data-driven spinal cord stimulation technologies for neurorehabilitation in SCI.",[471],"Spinal Cord Injury",[471,473,474,217,475,476],"Transcutaneous Spinal Cord Stimulation (tSCS)","Closed-Loop Neuromodulation","Wearable Sensors","Neurorehabilitation","2026-03-01",{"date":479,"type":41},"2026-03-05",{"date":481,"type":23},"2026-05",{"date":483,"type":23},"2028-09",{"name":47,"class":48},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100627709","diabetes-in-asians-at-risk-in-youth-100627709","NCT07452159","Diabetes In Asians at Risk in Youth","Diabetes in Asians at Risk in Youth","DIARY","Inclusion Criteria:\n\n* Asian\u002FPart Asian ethnicity living in Singapore, not known to have diabetes\n\nExclusion Criteria:\n\n* Pregnancy women\n* Non-Asian ethnicity\n* On active cancer\u002Fsteroid therapy\n* Haemoglobinopathies or haemolytic anaemia\n* Previous bariatric surgery\n* Previous partial\u002Ftotal pancreatectomy","39 Years",{"count":495,"type":23},3000,"This observational study aims to develop novel contemporary risk factor tools for detecting young onset diabetes (under 40y) in young Asians in Singapore. The investigators aim to recruit 3000 people not currently known to have diabetes, selected across age and Body Mass Index categories, and perform formal diagnostic tests for diabetes (oral glucose tolerance test and HbA1c). The participants will also undergo continuous glucose monitoring sensor, keep a food diary, and undergo body composition analysis using bioimpedance analysis, handgrip measurements for muscle strength, and sociobehavioural profiling through download of a curated list of social media interactions. The participants will also have a blood sample retrieved and stored for subsequent comparison between people with normal glucose versus abnormal glucose levels. The whole group will also have another blood sample stored for whole gene analysis.",[498],"Young Onset Asian Diabetes (Under 40 Years)",[500,501,502,503],"Young onset diabetes","Asian","Risk factors","contemporary",{"date":479,"type":41},{"date":506,"type":23},"2026-03-18",{"date":508,"type":23},"2029-01-02",{"name":47,"class":48},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":379,"maxAge":4,"enrollmentInfo":518,"targetDuration":520,"studyType":154,"phases":4,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":537},"100626642","predictors-of-decompensation-acute-on-chronic-liver-failure-and-mortality-in-liver-cirrhosis-100626642","NCT07438288","Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis","Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)","SoLiDaRity","Inclusion Criteria:\n\n1. Patients with clinical diagnosis of liver cirrhosis\n2. Age 18 years and above (parental consent required if below 21 years)\n3. Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* No clinical evidence of liver cirrhosis\n* Not willing to provide informed consent",{"count":519,"type":23},2200,"10 Years","The purpose of this study is to identify factors that predict the development of decompensation, acute-on-chronic liver failure (ACLF) and death in patients with liver cirrhosis. Clinical data will be retrieved from existing hospital records. This information may help doctors to identify patients with cirrhosis who are at risk of deterioration earlier (before they develop complications) and to develop effective treatment strategies to prevent or delay these complications.\n\nThis study is designed as a prospective, non-interventional, observational study. This means that if you agree to participate in the study, you will not be required to undergo any additional hospital visits, tests, procedures or interventions other than the usual standard-of-care management that your doctor will provide. If you consent to participate in this study, you will be providing the study investigators permission to review and analyse your clinical data from the hospital clinical records. Your data will be collected throughout the course of your disease until liver transplantation or death.",[523],"Cirrhosis and Chronic Liver Disease",[525,526,527,528],"Cirrhosis","Decompensation","Acute-on-chronic liver failure","Death","2026-02-22",{"date":531,"type":41},"2026-02-27",{"date":533,"type":41},"2022-08-12",{"date":535,"type":23},"2032-08-12",{"name":47,"class":48},3,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":465,"enrollmentInfo":545,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":561,"leadSponsor":562,"locationsCount":49},"100626647","home-based-digital-rehabilitation-program-optimized-with-transcutaneous-spinal-cord-stimulation-for-upper-limb-functional-enhancement-in-tetraplegia-hope-a-safety-efficacy-and-feasibility-study-100626647","NCT07438353","Home-Based Digital Rehabilitation Program Optimized With Transcutaneous Spinal Cord Stimulation for Upper Limb Functional Enhancement in Tetraplegia (HOPE): A Safety, Efficacy, and Feasibility Study","HOPE","Inclusion Criteria:\n\nParticipant\n\n* Age 21 -75 years;\n* Non-progressive cervical SCI\u002Fspinal cord dysfunction (traumatic or non-traumatic);\n* Duration of SCI\u002Fspinal cord dysfunction more than or equal to 12 months;\n* ASIA Impairment scale (AIS B, C, or D) with impaired upper limb function;\n* At least one hand capable of grasp and pinch, with or without assistive modification;\n* International Standards for Neurological Classification of Spinal Cord Injury-Upper Extremity Measurement Scale (ISNCSCI-UEMS) more than or equal to 20;\n* Able to maintain an upright sitting position for at least 30 minutes;\n* No contraindication for tSCS (e.g., no pacemakers or other implantable stimulators);\n* Motivated and able to engage in a daily home-based rehabilitation program;\n* Availability of a dedicated care-giver to set up digital home-based therapy program\n\nCaregiver\n\n* Age 21 -75 years;\n* As identified by the patient as the caregiver;\n* Willing to participate in the study\n\nExclusion Criteria:\n\nParticipant\n\n* Significant or unstable medical co-morbidities including uncontrolled cardiopulmonary disease, severe cognitive impairment, severe dysautonomia, as determined by the investigator;\n* Pregnancy;\n* History of other neurologic conditions affecting upper limb function, such as stroke, multiple sclerosis, or traumatic brain injury;\n* Known history of peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc);\n* Ongoing treatment for cancer;\n* Skin conditions or active cancerous lesion that limit the application of tSCS electrodes\n* Known contraindication for tSCS (pacemakers or other implantable stimulators);\n* Prior exposure to tSCS treatment;\n* Inability to provide informed consent.\n\nCaregiver:\n\n• Inability to provide informed consent.",{"count":546,"type":23},9,[26],"Individuals with chronic cervical spinal cord injury (SCI) and tetraplegia commonly experience persistent impairment in upper limb function, leading to reduced independence and quality of life. Transcutaneous spinal cord stimulation (tSCS) is a non-invasive neuromodulation technique that has demonstrated potential to improve upper limb strength and function when combined with rehabilitation. However, access to tSCS is limited in Singapore due to cost, regulatory barriers, and the need for frequent outpatient therapy.\n\nThis study evaluates the safety, efficacy, and feasibility of a home-based digital rehabilitation program incorporating tSCS delivered using a commercially available neuromuscular electrical stimulation (NMES) device. Using a prospective, open-label single-case experimental design with multiple baselines across participants, individuals with chronic, non-progressive cervical SCI will receive daily home-based tSCS combined with an mobile application-guided upper limb exercise program. Upper limb function, quality of life, feasibility, and safety outcomes will be assessed longitudinally over a 22-week study period.",[471,550],"Quadriplegia\u002FTetraplegia",[552,553,554,555,556,557,558,471],"Transcutaneous spinal cord stimulation","Tetraplegia","Telerehabilitation","Rehabilitation Technology","Digital Rehabilitation","Home-Based Rehabilitation","Neuromodulation",{"date":531,"type":41},{"date":454,"type":23},{"date":45,"type":23},{"name":47,"class":48},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":570,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":571,"conditions":572,"keywords":577,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":49},"100621301","scalp-hair-metabolomics-in-severe-obesity-100621301","NCT07368842","Scalp Hair Metabolomics in Severe Obesity","Scalp Hair Metabolomics as a Novel Biomarker of Poor Metabolic Health in Individuals With Severe Obesity","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent\n\nHealthy weight controls:\n\n1. BMI of 18.5-24.9 kg\u002Fm2\n2. No chronic disease\n3. No long-term medications\n\nSevere obesity:\n\n1. BMI of \\> 32.5 kg\u002Fm2\n2. Scheduled to undergo bariatric surgery\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Any factors likely to limit adherence to study protocol\n3. Any history of autoimmune or scarring alopecia (eg. alopecia areata, discoid lupus, lichen planopilaris)",{"count":98,"type":23},"The purpose of this research study is to investigate how body weight and weight-loss surgery affect the natural chemicals found in scalp hair over time. We will also find out how common and severe hair thinning\u002Fhair loss and muscle loss are in the first 6 months after bariatric surgery.",[573,574,575,576],"Obesity & Overweight","Hair Loss","Metabolomics","Bariatric Surgery",[578,579,580,581],"obesity","hair loss","metabolomics","bariatric surgery","2026-02-11",{"date":584,"type":41},"2026-02-13",{"date":586,"type":41},"2026-02-07",{"date":588,"type":23},"2028-02",{"name":47,"class":48},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":597,"targetDuration":4,"studyType":24,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":226},"100603188","care-coach-led-integrated-palliative-surgical-oncology-and-rehabilitation-care-model-for-advanced-cancer-patients-100603188","NCT07133269","Care Coach-led Integrated Palliative Surgical Oncology and Rehabilitation Care Model for Advanced Cancer Patients","Effectiveness of A Care Coach-led Integrated Palliative Surgical Oncology and Rehabilitation Care Model in Patients With Advanced Cancer Undergoing Major Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n(i) Patients:\n\n1. Aged 21 and above,\n2. Diagnosis of advanced cancer, i.e. stage 3 or 4 solid organ cancer or diagnosed with cancer that requires complex surgery,\n3. Planned for elective major surgery (Table of Surgical Procedures (TOSP) table code 4 or more or surgery involves more than one surgical discipline,\n4. Able to speak and read English or Chinese\n\n(ii) Caregivers:\n\n1. Age 21 and above,\n2. Unpaid family or informal caregiver who takes direct care of the patient's day-to-day and healthcare needs, or ensures provision of care to meet the needs, or who is the decision maker with regard to the patient's needs and healthcare,\n3. Able to speak and read English or Chinese.\n\n(iii) Healthcare Providers (Qualitative interview only):\n\n1. Age 21 and above,\n2. Currently working as a Healthcare professional at SGH or NCCS and involved in this study.\n\nExclusion Criteria:\n\n(i) Patients:\n\n1. Patient refusal,\n2. Have complex PC needs requiring specialty palliative care (SPC) intervention before surgery,\n3. Active mental illness or severe dementia and certified unfit to make medical decision by a specialist physician,\n4. Scheduled for Emergency surgery.\n\n(ii) Caregivers:\n\n1\\. Unwilling to participate in the study.\n\n(iii) Healthcare Providers (Qualitative interview only):\n\n1\\. Unwilling to participate in the Qualitative interview.",{"count":598,"type":23},770,[26],"Advanced cancer is a life-limiting condition that can negatively impact quality of life and function. Patients often suffer from physical, emotional, social, spiritual, and decision-making issues. As such, most would benefit from basic palliative care (PC) which includes establishing goals of care through serious illness conversations (SIC), managing basic pain and other symptoms and addressing psychosocial needs, among others. Patients with advanced cancer are also at higher risk of functional decline due to receiving multiple concurrent treatments. Yet, among patients with advanced cancer undergoing major surgery, there has been little consideration of PC and functional needs.\n\nThe palliative surgical care model is a care model in which PC educated surgical oncology teams deliver basic PC, allowing sustainable PC provision to an increasing number of patients living with advanced cancer. In a local pilot palliative surgical care model, it was found that a care coach-led palliative surgical oncology (PSO) care model significantly increased palliative care delivery, ensuring more consistent and comprehensive support for patients. In addition, cancer rehabilitation delivered by rehabilitation professionals addresses functional impairments during the cancer journey, restoring and\u002For maintaining function and improving quality of life. It also plays a preventive role before surgery, a restorative role during treatment, and a supportive role during cancer progression.\n\nTherefore, to address longitudinal PC and functional needs, an integrated care coach-led palliative surgical oncology rehabilitation (PSO+R) care model involving PC-trained care coaches, surgical oncology teams, rehabilitation professionals, supported by specialist palliative care (SPC) physicians who will provide PC and cancer rehabilitation throughout the patient's advanced cancer journey, is proposed.",[602],"Advanced Cancer",[604,605,606,607,608,609],"Palliative Care","Advancer cancer","Cancer rehabilitation","Surgical Oncology","Care coach","Quality of Life",{"date":611,"type":41},"2026-02-12",{"date":613,"type":41},"2025-08-20",{"date":615,"type":23},"2028-04",{"name":47,"class":48},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":624,"minAge":19,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":24,"phases":627,"briefSummary":628,"conditions":629,"keywords":631,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":49},"100614685","focal-or-radical-therapy-a-lesion-based-molecular-evaluation-in-prostate-cancer-100614685","NCT07282808","Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer","FLAME-PC","Inclusion Criteria:\n\n* Prostate Adenocarcinoma\n* Grade Group 2-4\n* MRI lesion size ≤3ml for single lesions ≤1.5ml for 2 lesions\n* no gross EPE\n* assessed to be completely ablatable with margin with focal therapy.\n\nExclusion Criteria:\n\n* Grade Group 5 cancer\n* gross EPE\n* multifocal (\\>2) clinically significant prostate cancer\n* unablatable location (very apical, basal tumors, or otherwise determined by procedurist).","MALE",{"count":626,"type":23},130,[26],"Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems.\n\nIn a prospective observational expansion of a phase II clinical trial (ProAMFocal), 80% of patients with small, localized prostate cancers treated with FT had no cancer recurrence at one year, and 70% at 3 years after treatment. The investigators studied the genetic makeup of each cancer, and found that certain genetic markers and cancer subtypes were better at predicting recurrence than standard clinical measures.\n\nBased on this, the investigators are launching the FLAME-PC trial. In this study, all patients who qualify for FT will first undergo genetic profiling of their cancer. Patients with favorable profiles (low risk based on genetic markers) will receive FT, while those with high-risk profiles will be advised to undergo standard treatments like prostate removal or radiation.\n\nThe investigators current main goal is to test if genetic profiling can help us better select patients for FT. They believe that patients chosen using this method will have low recurrence rates (\\\u003C10%) compared to those in their previous study (20-30%). FLAME-PC aims to show that personalized treatment based on genetic profiling can improve outcomes for prostate cancer patients, offering effective cancer control with fewer side effects.",[630],"Prostate Cancer",[632,633,634,635,636,637],"focal therapy","decipher","cryotherapy","irreversible electroporation","hifu","biomarker","2026-01-06",{"date":640,"type":41},"2026-01-08",{"date":642,"type":23},"2026-01",{"date":644,"type":23},"2048-09",{"name":47,"class":48},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":653,"targetDuration":4,"studyType":24,"phases":654,"briefSummary":655,"conditions":656,"keywords":658,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":4},"100614864","dietary-glycine-supplementation-in-metabolic-dysfunction-associated-steatotic-liver-disease-100614864","NCT07285135","Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease","Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent.\n\nMASLD group:\n\n1. Hepatic steatosis on MRI\n2. BMI of 25-50 kg\u002Fm2\n\nControls:\n\n1. Absence of hepatic steatosis on MRI\n2. BMI of 18.5-24.9 kg\u002Fm2\n3. No chronic disease\n4. No long-term medications\n\nExclusion Criteria:\n\n1. Uncontrolled diabetes (HbA1c \\> 8%)\n2. Type 1 Diabetes Mellitus\n3. Clinically significant anemia (Haemoglobin \\\u003C 10 g\u002FdL)\n4. Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis\n5. Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)\n6. Glomerular filtration rate (GFR \\\u003C 30 ml\u002Fmin)\n7. Serum alanine transaminase (ALT) \\> 3x upper limit of normal (ULN)\n8. Serum aspartate transaminase (AST) \\> 3x ULN\n9. Liver cirrhosis\n10. Significant alcohol consumption (\\> 20g\u002Fday for women and \\>30g\u002Fday for men)\n11. Receiving weight loss medications or GLP-1 receptor agonists\n12. Pregnancy\n13. Uncontrolled thyroid disease\n14. Previous bariatric surgery\n15. Weight loss \\> 5% in the past 1 month\n16. Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI\n17. Claustrophobia\n18. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)",{"count":98,"type":23},[26],"The purpose of this research study is to determine whether taking glycine, a naturally occurring amino acid, as a supplement improves liver health measurements in individuals with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).\n\nThis project will be divided into two parts. The first part will be a case-control study comparing parameters of glycine-dependent metabolic pathways between individuals with MASLD and healthy controls. The second part will be a randomized placebo-controlled trial (RCT) to evaluate the impact of 26-week dietary glycine supplementation on parameters of liver health versus 26-week placebo in patients with MASLD.",[657],"Metabolic Dysfunction Associated Fatty Liver Disease",[659,660,661],"Fatty liver","Randomized controlled trial","glycine supplements","2025-12-02",{"date":664,"type":41},"2025-12-16",{"date":666,"type":23},"2025-12",{"date":668,"type":23},"2029-01",{"name":47,"class":48},{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":677,"targetDuration":4,"studyType":24,"phases":679,"briefSummary":680,"conditions":681,"keywords":684,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":694,"locationsCount":49},"100600466","assessment-of-revascularization-in-plantar-foot-of-diabetic-patients-pre-and-post-angioplasty-using-spatial-frequency-domain-imaging-100600466","NCT07097857","Assessment of Revascularization in Plantar Foot of Diabetic Patients Pre and Post Angioplasty Using Spatial Frequency Domain Imaging","Assessment of Revascularization in Plantar Foot of Diabetic Mellitus Patients Pre and Post Angioplasty Using Spatial Frequency Domain Imaging","Inclusion Criteria:\n\n* Patients of age 21 years and above with diabetes and undergoing lower limb arterial angioplasty\n* Willingness to participate in the study and undergo foot physiological assessments using SFDI\n\nExclusion Criteria:\n\n* Mentally incompetent, younger than 21 years of age, prisoners, pregnant or breastfeeding women\n* Patients unable to provide informed consent\n* Any medical condition which makes the candidate an inappropriate subject for study participation, in the investigator's judgment",{"count":678,"type":23},15,[26],"To explore the usefulness of SFDI in the assessment of revascularization pre and post intervention",[682,683],"Peripheral Arterial Disease(PAD)","Imaging Evaluation",[685,686,687],"Spatial Frequency Domain Imaging","Peripheral Arterial Disease","Non-invasive imaging","2025-07-24",{"date":690,"type":41},"2025-07-31",{"date":692,"type":41},"2024-10-02",{"date":666,"type":23},{"name":47,"class":48},""]